Science & Technology

IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine

Department of Health and Human Services — National Institutes of Health

Opportunity #: 2SB1AI120269-04A1

Award Ceiling

$1.0M

Award Floor

$1.0M

Close Date

Jun 30, 2026

107 days left

Total Funding

$1.0M

Expected Awards

Posted Date

Jul 7, 2023

Cost Sharing Required

Grants.gov ID

sbir-2SB1AI120269-04A1

Description

SBIR Phase Phase II award: "IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine" awarded to FLUGEN INC in MADISON, Wisconsin. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,048,815. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.